SpyGlass director files Form 3 with no holdings

SpyGlass Pharma, Inc. director Zachary Scheiner filed an initial Form 3 beneficial ownership report.

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. director Zachary Scheiner filed an initial Form 3 beneficial ownership report. The filing, effective as of 02/05/2026, states that no securities of SpyGlass Pharma are beneficially owned. The form is signed by attorney-in-fact Brian Aukshunas under a power of attorney.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SpyGlass Pharma (SGP) Form 3 filing for Zachary Scheiner report?

The Form 3 for Zachary Scheiner, a director of SpyGlass Pharma, reports his initial beneficial ownership status. It states that, as of February 5, 2026, no SpyGlass Pharma securities are beneficially owned, indicating no reportable holdings at that time.

What is the effective date of Zachary Scheiner’s Form 3 with SpyGlass Pharma (SGP)?

The effective date of Zachary Scheiner’s Form 3 is February 5, 2026. This date marks the event requiring the ownership statement and is the reference point for his reported beneficial ownership status, which is shown as no securities beneficially owned.

What is Zachary Scheiner’s relationship to SpyGlass Pharma (SGP) in this Form 3?

In this Form 3, Zachary Scheiner is identified as a director of SpyGlass Pharma, Inc. The filing confirms his role by checking the “Director” box and clarifies that he is neither an officer nor a ten percent owner of the company.

Does the SpyGlass Pharma (SGP) Form 3 show any securities beneficially owned by Zachary Scheiner?

No, the Form 3 explicitly states that no securities are beneficially owned. This statement appears in the remarks section, indicating that, at the time of the filing, there were no reportable non-derivative or derivative securities held by the reporting person.

Who signed the SpyGlass Pharma (SGP) Form 3 for Zachary Scheiner?

The Form 3 is signed by Brian Aukshunas as attorney-in-fact for Zachary Scheiner. The signature line reads “/s/ Brian Aukshunas, as Attorney-in-Fact,” and is dated February 5, 2026, reflecting the authorized representative executing the filing.

What additional document is referenced in Zachary Scheiner’s SpyGlass Pharma (SGP) Form 3?

The Form 3 references Exhibit 24, a power of attorney. This exhibit authorizes the attorney-in-fact, identified as Brian Aukshunas, to sign and submit the ownership report on behalf of Zachary Scheiner in connection with his role at SpyGlass Pharma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 01:11 PM EST Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Scheiner Zachary

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2026

3. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.